Biomarkers for assessing peripheral neuropathy response to cancer treatment

US9605317B2 · kind B2 · utility

Assignee

• Janssen Pharmaceuticals, Inc. · BE

Inventors

• Nadine Cohen · Princeton, US
• Reyna Favis · Iselin, US
• Qingqin S. Li · Flemington, US
• Deborah Ricci · Ringoes, US
• Yu Sun · Toronto, CA
• Helgi van de Velde · Retie, BE

Key dates

• Filing date: Mar 24, 2010
• Grant date: Mar 28, 2017
• Expiry date: Jun 29, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12Q2600/172
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

The present invention provides methods for identifying patients at increased risk of developing an adverse neurological event in response to a cancer treatment. Methods also include modifying the treatment regimen of said patent dependent on the presence or absence of biomarkers in the patient.